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Potent antileishmanial activity has recently been described in vivo when certain 
2-substituted quinoline alkaloids are administered to mice with cutaneous leishman- 
iasis. We now report the antileishmanial activity of four 2-substituted quinoline 
alkaloids, namely chimanine D or 2 4  l',T-tr.ans-epoxypropyl) quinoline (I), 2-n; 
> i  ' propylquinoline (II), 2-styrylquinoline (III) and 2-(2'-hydroxypropyl) quinoline (IV), 
for experimental treatment of visceral leishmaniasis in infected BALB/c mice. 
Subcutaneous treatment with chimanine D for 10 days at 0.54 mmol/kg per day 
resulted in 8 6 6 %  parasite suppression in the liver. Oral administration of 
0.54 mmol/kg of 2-n-propylquinoline once daily for 5 or 10 days to 
L. donovani-infected mice suppressed parasite burdens in liver by 87.8 and 99.9%, 
respectively. Cutaneous administration of meglumine antimonate for 1 O days 
resulted in 97.4% parasite suppression in the liver. This study is, to our knowledge, 
the first to demonstrate the activity of 2-substituted quinoline alkaloids in experi- 
mental treatment of visceral leishmaniasis. Further biological and chemical studies 
of these products might yet prove helpful for the development of new antileish- 
mania1 drugs. 
k 
? Introduction 
Visceral leishmaniasis or kala-azar is a fatal human disease caused by Leishmania 
donovani. This disease is endemic in many parts of the tropical and subtropical regions 
of the world. The estimated global prevalence is 12 million, with 400,000 to 2,000,000 
new cases reported each year. The World Health Organization estimates that approxi- 
mately 350 million people live in endemic areas (WHO, 1990). Drugs currently 
available for treatment of kala-azar are potentially toxic, are inconvenient to admin- 
ister and frequently (10-15%) give rise to clinical resistance (Berman, 1988; Croft, 
1988; Kuhlencord et al., 1992). Drugs of first choice are pentavalent antimonials such 
as sodium stibogluconate and meglumine antimonate. Second-line drugs are diamidines 
(pentamidine) and amphotericin B, which although effective in kala-azar, are of limited 
use because of their toxicity. 
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Other treatments for kala-azar are now under investigation. These include liposomal 
amphothericin B (Croft, Davidson & Thornton, 199 l), allopurinol and derivatives 
(Kager et al., 1981; Chung et al., 1985) bis(benzy1) polyamine analogues (Baumann, 
McCann & Bitonti, 1991), formycin B (Berman et al., 1983), 8-aminoquinoline deriva- 
tives (Kinnamon et al., 1978; Neal, 1987), an alkylphosphocholine compound, hexa- 
decylphosphocholine (Croft et al., 1987; Kuhlencord et al., 1992), acivicin (Mukherjee, 
Roy & Bhaduri, 1990) and recently hydroxynaphthoquinones, whose activity in vivo is 
limited (Croft et al., 1992). 
Recent reports of resistance to antimonial drugs in India and in Sudan (WHO, 1991), 
and numerous cases of visceral leishmaniasis in patients with AIDS have been 
described (Peters et al., 1990). For these reasons, new chemotherapeutic agents active 
against visceral leishmaniasis are urgently required, and such new compounds should 
be administered by the oral route in order to facilitate their use. 
We have already described the efficacy of 2-substituted quinolines for treatment of 
cutaneous New World leishmaniasis, Leishmania ainazonensis and Leishmania venezue- 
lensis and the synthesis of several 2-substituted quinolines (Fournet et al., 1992), 
including a 2-substituted three-carbon chain quinoline and a 2-substituted phenylethyl 
chain. The aim of this study was to evaluate the activity of 2-substituted quinolines in 
BALB/c mice intravenously infected with L. donovani. Different routes of administra- 
tion, namely intraperitoneal, subcutaneous and oral were investigated. 
Materials and methods 
Drugs 
The quinoline alkaloids, 2-n-propylquinoline (I), 2-(1’,2’-trans-epoxypropyl) quinoline 
or chimanine D (II) were isolated from the Bolivian plant, Galipea IongiJlora Krause 
(Rutaceae) by fractionation and purification monitored by bioassay (Fournet et al., 
1991). 2-styrylquinoline (III) and (2-(2’-hydroxypropyl) quinoline (IV) were synthesized 
as described in PCT Patent (Fournet et al., 1992). The structures of these products are 
shown in the Figure. N-methylglucamine antimonate (meglumine antimonate, 
GlucantimeR) equivalent to 0.28 mg Sb”/mL was obtained from Rhône-Poulenc, 
France. 
Animals 
Female BALB/c mice (weight 18-20 g) were supplied by the IFFA-CREDO, France 
and male hamsters (weight 90-1 20 g) (Mesocricetus auratus) by the Animal Production 
Centre, France. The latter were used to maintain the parasite. 
Parasites 
The Ethiopian strain of L. donovani (MHOM/ET/67/L82; LV9) was obtained from Dr 
Simon L. Croft (London School of Hygiene, London, UK) and maintained by serial 
passage in hamsters at the time of infection. Parasites were obtained by homogenizing 
the spleen of a freshly killed hamster, infected for approximately 4 weeks in RPMI 1640 
medium containing 10% fetal calf serum (Gibco). The hamsters were infected by 
intracardiai injection of lo8 amastigotes of L. donovani in 100 pL of medium. 
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Figure. Structures of chimanine D (I), 2-n-propylquinoline (II), Zstyrylquinoline (III) and 2-(2-hydroxy- 
propy1)quinoline (IV). 
Parasite suppression and parasite distribution 
Ten BALB/c mice were infected via the tail vein (without anaesthetic) by injection of 
5 x lo6 amastigotes in 100 pL medium derived from homogenates of infected hamster 
spleens. One day after the last drug administration, the mice were weighed, killed and 
the livers and spleens removed and weighed. Liver impressions were prepared and 
stained by Giemsa and the numbers of amastigotes per host liver cell nucleus were 
counted (500 liver nuclei of each animal were examined under oil immersion). The 
number of amastigotes per organ per nucleus x liver mass in mg x (2 x lo5) is approxi- 
mately equal to the total number of amastigotes per liver (Stauber, Franchino & Grun, 
1958). Parasite suppression was calculated from the ratio of the mean liver amastigote 
counts of drug-treated mice and the mean liver amastigotes counts of untreated mice 
multiplied by 100 to obtain the percentage of parasite suppression. Pieces of liver were 
cultured in 25 cm2 tissue culture flasks (T25, Falcon) on 90 mL RPMI 1640 medium 
containing 10% fetal calf serum, 1 mL of solution of meglumine antimonate 
(29.4 mg/L), 2 mL of Schneider medium and antibiotics (100 U1 of penicillin and 
100 pg of streptomycin/mL). The cultures were observed daily for 10 days. 
Antimicrobial treatnzeiit 
The animals were treated intraperitoneally, subcutaneously or orally once daily with 
the experimental drugs for 5 or 10 days during 1 or 2 week periods. The treatments 
were initiated 1 week after parasite inoculation. The BALB/c mice were weighed before 
treatment began. One week after infection the mice were randomly divided into groups 
of ten. Drugs were made up in 100 pL 1 %O carboxymethylcellulose (CMC) and Tween 
SO and administered daily on days 5 and 10 by intraperitoneal, subcutaneous or oral 
routes. Quinoline alkaloids were tested at dose level of 0.54 mmol/kg body weightlday 
for 5 or 10 days. Quinoline alkaloids were also administered in CMC-Tween by gavage. 
In each experiment, mice were treated for 5 or 10 days with the reference drug, 
N-methylglucamine antimonate at a dose of 56 mg of Sb"/kg/day, which corresponds to 
200 mg/kg or 0.54 mmol/kg. The reference drug was dissolved in 100 pL of 
CMC-Tween and administered by intraperitoneal or subcutaneous routes. In each 
protocol two groups of ten mice were treated daily for 5 and 10 days and ten infected 
mice were untreated and served as controls. 
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Presentation and statistical analysis of data 
Parasite suppression was calculated from the ratio of the mean amastigote counts in the 
drug-treated groups to the mean amastigote counts in the untreated control groups. 
The Student t-test was used for the statistical analysis of all data (P  > 0.05). 
Results 
Intraperitoneal treatment 
Four quinoline alkaloids were used in this study: chimanine D (I), 2-it-propylquinoline 
(II), 2-styrylquinoline (III) and 2-(2'-hydroxypropyl) quinoline (IV). Table I shows that 
the weights of spleen and liver of all infected mice increased after 2 weeks of experiment 
and 5 days of treatment with quinoline alkaloids or antimonial compound. The greatest 
increase in splenic and liver weight was (total weight of 240 mg and 1.96 g, respectively) 
in mice treated with chimanine D (I). The liver and spleen weights of mice treated with 
other compounds and meglumine antimonate were identical. Table I also shows that 
suppression of the parasite burden in livers of BALB/c mice treated with antimony 
compounds was reduced by 97.2% and 79.6% in mice treated with 2-styrylquinoline 
(III). With other compounds we obtained suppression of parasites between 62.4% with 
2-n-propylquinoline (II) and 55.7% with 2-(2-hydroxypropyl)quinoline (IV). We did 
not observe any side-effects of these quinoline alkaloids during these experiments: 
necrosis at the site of drug inoculation or loss of weight were not observed. 
Homogenates of liver of mice treated for 5 days with quinoline alkaloids and meglu- 
mine antimonate were cultured and observed for parasite growth. All cultures of 
homogenates of liver from meglumine antimonate or quinoline alkaloid treated mice 
were positive after 10 days of incubation. 
Table T. Efficacy of four quinoline alkaloids and meglumine antimonate administered 
intraperitonally to L. doriovani infected BALB/c micea 
Treatment 
Uninfected 
No drug (control) 
Meglumine antimonate" 
Chimanine D (I) 
2-n-propylquinoline (II) 
2-styrylquinoline (III) 
2-(2'-hydroxypropyl) 
quinoline (IV) 
Dose Liver wt (g) 
(mmol/kg) (mean f s . ~ . ) ~  
1.27 f 0.07 
1.57 f 0.09 
0.54 x 5 I.58f0.08 
0.54 x 5 I .96 f 0.09 
0.70 x 5 1.53 f 0.12 
0.54 x 5 1.52 f 0.08 
0.54 x 5 1.53f0.10 
Spleen wt 
(mg) 
(mean f S.E.)" 
107f13 
176+14 
168425 
240 f 30 
190+25 
169f30 
180f30 
% Suppression of 
parasites load in 
the liver" 
- 
97.2 
57 
62.4 
79.6 
55.7 
"Mice (n = 10) were treated intraperitoneally with quinoline alkaloids or meglumine antimonate once per 
hMean liver or spleen weightfstandard error. 
'Values including the liver weight (mg) x number of amastigotes/500 liver nuclei (see Stauber er al., 1958), 
compared with data for mice receiving 100 pL CMC-Tween 80 only. Each treatment and control group 
included ten mice. 
"0.54 mmol = antimony 56 mg/kg. 
day for 5 days, beginning on day 7. 
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Table II. Efficacy of four quinoline alkaloids and meglumine antimonate administered 
subcutaneously to Leiskinania donovani infected BALB/c mice" 1 
Treatment 
Spleen wt % Suppression of 
Dose Liver wt (9) (mg) parasites load in 
(mmol/kg) (mean -I S.E.)' (mean the liver' 
~ ~ 
Untreated 
Meglumine antimonate" 054 x 5 
0.54 x 10 
Chimanine D (I) 0.54 x 5 
0.54 x 10 
2-rz-propylquinoline (II) 0.54 x 5 
0.54 x 10 
2-styrylquinoline (III) 0.20 x 5 
5. 0.20 x 10 
1.61 -10.20 
1.69 f 0.1 8 
1.37$0.20 
1*52+0.13 
1 e46 + 0.20 
1-57 5 0.1 3 
1.69 f 0.1 1 
1-85 f 0.27 
1.83f0.29 
270 f 95 
210f35 
2005 120 
160f30 
200 5 60 
190$20 
250 5 40 
240 & 80 
350+ 130 
- 
89.9 
97.4 
69.5 
86.6 
76.3 
67.8 
37.1 
26.3 
"Mice (n = 10) were treated subcutaneously with quinoline alkaloids or meglumine antimonate once per 
bMean liver or spleen weighttstandard error. 
Values including the liver weight (mg) x number of amastigotes/500 liver nuclei (see Stauber et al., 1958), 
compared with data for mice receiving 100 p L  CMC-Tween 80 only. Each treatment and control group 
included ten mice. 
day for 5 or 10 days, beginning on day 7. 
d0.54 mmol = antimony 56 mg/kg. 
Subcutaneous treatment 
The liver and spleen weights of mice treated with the antimonial compound and with 
chimanine D (I) and 2-n-propylquinoline (II) were equivalent. Subcutaneous treatment 
with chimanine D (I) a t  0.54 mmol/kg once per day for 5 days caused 69.5% 
suppression in the spleen parasite count compared with untreated mice (Table 11). 
Prolonging the treatment by 5 days produced a better effect with 86.6% suppression of 
liver parasites. In this study, subcutaneous meglumine antimonate treatment for 5 and 
10 days suppressed spleen parasites respectively by 89.9% and 974% compared with 
infected untreated mice. Treatment with 2-n-propylquinoline at 0.54 mmol/kg for 5 or 
10 days resulted in suppression of the parasites by 76.3% and 67.8%. Preliminary 
toxicological evaluation of quinoline alkaloids I and IT in mice indicated that the acute 
intraperitoneal 50% lethal dose was greater than 400 mg/kg. The third quinoline 
alkaloid 2-styrylquinoline (III) tested did not show efficacy against L. donovani when it 
was administered at 46 mg/kg once a day for 5 or 10 days. We decreased the dose of 
this compound because of fatal toxicity when it was administered at the same molecular 
concentration (0.54 mmol/kg) as the other quinoline alkaloids and reference drug 
1 
i 
,) \ (meglumine antimonate). 
Oral treatmen2 
Two quinoline alkaloids were administered by the oral route, chimanine D (I) and 
2-n-propylquinoline (II) a t  0.54 mmol/kg for 5 and 10 days, 1 week after parasitic 
infection. The other compound, 2-styrylquinoline (TIT) was given at 0.2 mmol/kg under 
the same conditions. As shown in Table III, both chimanine D (I), 2-n-propylquinoline 
(IT) and meglumine antimonate were effective in reducing liver and spleen weight when 9 
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Table III. Parasite suppression in leishmania-infected mice treated with quinoline alkaloids orally 
for 5 or 10 days. 
~~~ 
Spleen wt % Suppression of 
Dose Liver wt (g) (mg) parasites load in 
Treatment” (mmol/kg) (meanfs.E.)b (mean &S.E.)’ the liver‘ 
Untreated 1.61 40.20 270195 - 
Meglumine antimonated 0.54 x 5 1.69 k0.18 210k35 89.8 
0.54 x 10 1.37 E0.20 200k 120 974  
Chimanine D (I) 0.54 x 5 1.4050.14 140420 729 
0.54 x 10 1.45 4 0.14 200 1 5 0  62.0 
2-n-propylquinoline (II) 0.54 x 5 1.51 f0.06 150+20 87% 
0.54 x 10 1.37 5 0.13 200 40 99.9 
2-styrylquinoline (III) 0.20 x 5 1.46 4 0.1 3 200 f 90 426 
0.20 x 10 1.62 4028  3304  110 6.1 
“Mice (n = 10) were treated orally with quinoline alkaloids and subcutaneously with meglumine 
hMean liver or spleen weightkstandard error. 
Values including the liver weight (mg) x number of amastigotes/500 liver nuclei (see Stauber et al., 1958), 
compared with data for mice receiving 100 pL CMC-Tween SO only. Each treatment and control group 
included ten mice. 
antimonate once per day for 5 or 10 days, beginning on day 7. 
d@54 mmol = antimony 56 mg/kg. 
given for 5 or 10 days compared with untreated groups. Treatment with 2-styrylquino- 
line (III) alone for 10 days resulted in a great increase of spleen weight. Oral treatment 
with 2-n-propylquinoline (0.54 mmol/kg) (II) and meglumine antimonate (56 mg of 
Sbv/kg) for a 5-day period produced an equivalent suppression of parasite load in the 
liver by 87.8% and 89+3%, respectively. Extending oral treatment to 10 days with 
2-n-propylquinoline (II) increased the effect of parasite suppression in the liver to 
99.9% 10 days’ subcutaneous treatment of infected mice with meglumine antimonate 
did not produce greater parasite suppression. In these experiments we did not observe 
any side-effects when mice were orally treated with chimane D (I) or 2-n-propylquino- 
line (II). Examination of the liver and spleen did not show any apparent toxicity. 
Discussion 
In a previous study (Fournet et al., 1991) we reported that subcutaneous treatment with 
quinoline alkaloids was effective against New World cutaneous leishmaniasis, 
L. amazonensis and L. venezuelensis in BALB/c mice. We now show that oral adminis- 
tration of one of these compounds, 2-n-propylquinoline (II), suppressed 99.9% of liver 
parasites and that another quinoline alkaloid, chimanine D (I) resulted 866% parasite 
suppression when it was given for 10 days at 0.54 mmol/kg by the subcutaneous route. 
In contrast, we found suppression of L. donovani by 974% in the liver when mice were 
treated with meglumine antimonate by the subcutaneous route for 10 days at 
56 mg/Sbv/kg/day. Oral administration of chimanine D (I) for 5 days resulted in lower 
parasite suppression (72.9%). Attempts to administer quinoline alkaloids by the 
parenteral route did not produce a similar effect on mice infected with L. donovani. 
Treatment of infected mice by the peritoneal route with quinoline alkaloids was not as 
effective as the antimony compound. 2-styrylquinoline (III) alone suppressed 79.6% of 
parasites in the liver. 
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The interesting oral activity of 2-12-propylquinoline (II) in the liver of mice may 
probably be explained by its excellent distribution within the reticuloendothelial 
system. In this study we have observed better antileishmanial activity of quinoline 
alkaloids which include a propyl chain, such as compounds I and II. Longer therapy or 
administration twice a day might enhance the efficacy of these compounds because of 
parasite suppression in the spleen or the liver. The reduced toxicity of oily compounds 
(such as quinoline alkaloids with 2-substituted three-carbon chain) will facilitate 
treatments of longer duration. The in vivo efficacy of oral 2-12-propylquinoline (II) and 
chimanine D (I) against L. donovani suggests that these agents should be evaluated for 
their therapeutic effects in dogs infected with visceral leishmaniasis. 
The efficacy of the 2-substituted quinoline alkaloids against cutaneous leishmaniasis 
of the New World and visceral leishmaniasis by parenteral and oral routes suggests that 
exploration of their potential should continue. This study is the first to our knowledge, 
to show the activity of 2-substituted quinoline alkaloids for treating experimental 
visceral leishmaniasis. We continue to explore the activity of these oral compounds and 
new analogues against L. donovani even though commercial motivation to develop 
drugs for most tropical diseases may be limited (Del Mar Sanz et al., 1991). 
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